Office Based Vergence and Accommodative Therapy and Intermittent Exotropia

June 26, 2018 updated by: Xiang Chen, Sun Yat-sen University

Pilot Study of Office Based Vergence and Accommodative Therapy as Treatment of Intermittent Exotropia

This pilot study is designed specifically to determine the short-term effect of OBVAT on intermittent exotropia in terms of 4 key areas (Standardizing reported outcomes of surgery for intermittent exotropia): control score, alignment, near stereoacuity and quality of life score. Result of this pilot study will be used to determine whether a full-scale RCT should be conducted to evaluate the short and long term effectiveness of OBVAT.

Study Overview

Status

Unknown

Detailed Description

All enrolled px received 16-20 sessions of OBVAT, 60 minutes per visit, one time per week; Home reinforcement, 15 minutes each time, five times per week.

  1. Primary outcome measure: A. Change in the office based intermittent exotropia control score
  2. Secondary outcome measures A. Change in Look And Cover, then Ten seconds of Observation Scale for Exotropia (LACTOSE) B. Change in Newcastle Control Score (NCS) C. Change in Chinese intermittent exotropia questionnaire (CIXTQ) D. Change in near stereopsis by Preschool randot near stereoacuity E. Change in size of distant deviation angle by prism alternating cover test F. Change in size of near deviation angle by prism alternating cover test

Study Type

Interventional

Enrollment (Anticipated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Guangdong
      • Guangzhou, Guangdong, China, 510000
        • Zhongshan Ophthalmic Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. 8 to 18 years old
  2. deviation meeting all of the following criteria: A. intermittent or constant exotropia at distance (mean of 3 baseline assessments of distance control> or = Grade 2) B. intermittent exotropia at near (at least 1 of 3 assessments of near control at the baseline visit Grade 2-4) C. distance and near exodeviation both between 15 to 35 prism diopters (PD) measured by prism and alternate cover test (PACT); D. near deviation not exceeding the distance deviation by >10PD by PACT (i.e., convergence insufficiency type IXT excluded)
  3. cycloplegic objective refraction spherical equivalent (SE) refractive error between -6.00 diopters (D)and +1.00 D inclusive in either eye
  4. Patients must be wearing the updated refractive correction (spectacles or contact lenses) for at least 1 week if refractive error (based on cycloplegic refraction performed within 6 months) meets any of the following:

    A. Myopia >-0.50 D spherical equivalent in either eye B. Anisometropia >1.00 D spherical equivalent C. Astigmatism in either eye >1.50 D

  5. Refractive correction must meet the following guidelines:

    A. Anisometropia spherical equivalent must be within 0.25 D of the full anisometropic difference B. Astigmatism cylinder must be within 0.25 D of full correction and axis must be within 5 degree C. For hyperopia and myopia, the spherical component can be reduced by investigator discretion provided reduction is symmetrical and results in residual (i.e., uncorrected) spherical equivalent refractive error that does not exceed +1.50 D spherical equivalent hyperopia or -0.50 D spherical equivalent myopia

  6. Gestational age >34 weeks
  7. Birth weight >1500 g
  8. No previous surgical or nonsurgical treatment for IXT other than single vision refractive correction (e.g. PALs, Bifocals, patching, or deliberate over-minus with spectacles more than 0.50 D)
  9. No vision therapy or orthoptics for any reason within the last year
  10. No prior strabismus surgery or botulinum injection, intraocular surgery, or refractive surgery
  11. No strabismus surgery planned
  12. vision correctable to at least 20/25 or better at distance and near in each eye.
  13. Px needs to have a computer at home which can connect to internet

Exclusion Criteria:

  1. Patient with nystagmus, restrictive or paretic strabismus
  2. Patient with amblyopia, which is defined as >or = 0.2 logarithm of the minimum angle of resolution units of interocular difference and > or = 0.3 logarithm of the minimum angle of resolution units in one eye ( Variability of stereoacuity in intermittent exotropia)
  3. Regular use of any ocular or systemic medications known to affect accommodation or vergence system, such as atropine, pirenzepine, and anti-epileptic medications in recent 3 months;
  4. developmental disability, attention deficit hyperactivity disorder(ADHD), or learning disability diagnosis in children that in the investigator's discretion would interfere with office-based treatment;
  5. Relocation anticipated for 2 years;
  6. Significant ocular or neurologic disorders (e.g. cerebral palsy) other than strabismus
  7. Vertical deviation greater than 1 pd in cover test
  8. Household member already in the study.
  9. Any eye care professional, ophthalmic technician, medical student, or optometry student

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Accommodative/vergence therapy
Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Office based intermittent exotropia control score
Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
Office based intermittent exotropia control score is an office based score to assess the control of intermittent exotropia. Minimum score is 0 (best score, phoria) and Maximum score is 5(worst score, constant tropia). Change in Office based intermittent exotropia control score after 14 weeks of vision therapy
Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Look And Cover, then Ten seconds of Observation Scale for Exotropia(LACTOSE)
Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
Look And Cover, then Ten seconds of Observation Scale for Exotropia (LACTOSE) is an office based score to assess the control of intermittent exotropia. Minimum score is 0 (best score, phoria) and Maximum score is 4(worst score, constant tropia). Change in score after 14 weeks of vision therapy.
Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
Newcastle Control Score
Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
Newcastle Control Score is an office based and home based score to assess the control of intermittent exotropia. Minimum score is 0 (best score) and Maximum score is 6(worst score). Change in score after 14 weeks of vision therapy.Change in score after 14 weeks of vision therapy.
Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
Chinese intermittent exotropia questionnaire
Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
Change in Chinese intermittent exotropia questionnaire after 14 weeks of vision therapy.
Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
Preschool randot near stereoacuity
Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
Change in near stereopsis by Preschool randot near stereoacuity after 14 weeks of vision therapy.
Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
deviation angle
Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
Change in size of distant deviation angle by prism alternating cover test after 14 weeks of vision therapy.
Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Chen xiang, associate chief physician

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2017

Primary Completion (Actual)

January 31, 2018

Study Completion (Anticipated)

December 30, 2018

Study Registration Dates

First Submitted

October 15, 2017

First Submitted That Met QC Criteria

October 23, 2017

First Posted (Actual)

October 26, 2017

Study Record Updates

Last Update Posted (Actual)

June 28, 2018

Last Update Submitted That Met QC Criteria

June 26, 2018

Last Verified

June 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intermittent Exotropia

Clinical Trials on accommodative/vergence therapy

Subscribe